The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer.
The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer.
复制标题
DOI：
--
复制
发表时间：
2011-12
影响因子：
2
通讯作者：
E. Herpel;K. Jensen;T. Muley;A. Warth;P. Schnabel;M. Meister;F. Herth;H. Dienemann;Michael Thomas;S. Gottschling
中科院分区：
文献类型：
--
作者：
E. Herpel;K. Jensen;T. Muley;A. Warth;P. Schnabel;M. Meister;F. Herth;H. Dienemann;Michael Thomas;S. Gottschling
在各种肿瘤实体中，肿瘤干细胞（CSC）抗原的表达已被证明对预后不利。然而，对于肺癌，相关数据缺乏且相互矛盾。患者和方法对133例完全切除的I/II期非小细胞肺癌（NSCLC）患者组织中的CSC抗原CD117/c-KIT、CD133和乳腺癌耐药蛋白-1 （BCRP1/ABCG2）进行免疫组织化学分析，中位随访时间为53.8个月。它们的表达与临床病理特征、血管生成特征及预后有关。结果Cox比例风险回归分析显示CSC抗原与无病生存期或总生存期（OS）无相关性。然而，在复发和肿瘤bbb3cm的患者亚组中，CD117的表达有恶化OS的趋势（风险比=2.6,95%，可信区间=0.8-8.3,p=0.080）。除了CD133在T1肿瘤中过度表达（p=0.001）外，CSC抗原与临床病理特征或血管生成特征无关。结论在切除的早期非小细胞肺癌中，CSC抗原与预后无相关性。然而，在复发和肿瘤面积大于3cm的患者中，CD117的表达可能预示更糟糕的OS。
BACKGROUND In various tumor entities, expression of cancer stem cell (CSC) antigens has been proven to be prognostically unfavorable. However, for lung cancer, the data are scant and conflicting. PATIENTS AND METHODS The CSC antigens CD117/c-KIT, CD133 and breast cancer resistance protein-1 (BCRP1/ABCG2) were immunohistochemically analyzed in tissues from a total of 133 completely resected stage I/II non-small cell lung cancer (NSCLC) patients with a median follow-up time of 53.8 months. Their expression was related to clinicopathological characteristics, angiogenic features and prognosis. RESULTS Cox proportional hazards regression analysis revealed no association between CSC antigens, disease-free survival or overall survival (OS). However, in the subgroup of patients with relapse and tumors >3 cm, there was a trend towards worse OS upon expression of CD117 (hazard ratio=2.6, 95%, confidence interval=0.8-8.3, p=0.080). Except for CD133, which was overrepresented in T1 tumors (p=0.001), the CSC antigens were not linked to clinico-pathological characteristics or angiogenic features. CONCLUSION In resected early-stage NSCLC, CSC antigens show no association with prognosis. However, in patients with relapse and tumors >3 cm, expression of CD117 might predict worse OS.